A large proportion of the type 2 diabetes (T2D) population have poor glycemic control, which puts individuals at high risk for chronic and debilitating microvascular and macrovascular complications

Early initiation of basal-bolus therapy quickly resolves glucotoxicity and lipotoxicity and has been shown to protect β-cell function; however, transition to basal-bolus therapy is often delayed due to therapeutic inertia

Increased use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) further delays basal-bolus transition; however, because the effectiveness of GLP-1 RA therapy is dependent on available insulin production, most individuals will eventually require insulin therapy

Numerous studies support the use of GLP-1 RA formulations in conjunction with basal insulin; fixed-ratio combinations of long-acting insulin and short-acting GLP-1 RA preparations are now available